Cis­platin, car­bo­platin short­ages raise ques­tions about im­pact on clin­i­cal tri­als 

At least two small biotechs have halt­ed clin­i­cal tri­als due to short­ages of cis­platin and car­bo­platin amid on­go­ing sup­ply is­sues for the chemother­a­pies com­mon­ly used in can­cer care.

Ear­li­er this month, Replimune told in­vestors that it put a Phase II clin­i­cal tri­al on hold un­til sup­ply of both drugs be­comes avail­able. The study is test­ing one of its on­colyt­ic virus­es in com­bi­na­tion with the stan­dard of care in pa­tients with squa­mous cell car­ci­no­ma of the head and neck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER